- SID Score
- 5.9/10
- Fair value
- $499.12
- Generated
- Sep 17, 2026
- Model
- claude-haiku-4-5-20251001
Eli Lilly and Company trades at $1,145.83 with a market capitalization of $906.5 billion, commanding a premium valuation with a P/E ratio of 49.16x. The stock is currently overbought relative to fundamental valuations, with a fair value estimate of $499.12 suggesting 55.2% downside risk, though analyst consensus remains bullish with an average price target of $1,055.92. The company demonstrates strong earnings momentum, consistently beating EPS estimates across recent quarters, yet the extremely low dividend yield of 0.01% indicates capital is being deployed toward growth rather than shareholder returns. With a SID Score of 5.9/10 and mixed factor grades, LLY presents a growth-driven narrative that requires careful evaluation against current valuation levels.
The company exhibits concerning value metrics with an F-grade for value, suggesting the stock is significantly overpriced relative to intrinsic value estimates. However, profitability receives a C-grade, indicating solid but not exceptional earnings quality, supported by recent quarter EPS beats (8.38 vs. 6.01 estimate on 2026-08-05 and 8.55 vs. 6.85 estimate on 2026-04-30). Growth prospects earn a B-grade, reflecting the pharmaceutical sector's potential for innovation and market expansion, though the massive valuation gap between current price and fair value estimate raises sustainability questions. The lack of recent annual financial data limits deeper analysis of revenue trends, margin expansion, and balance sheet strength, which are critical for pharmaceutical industry assessment.
The RSI(14) of 26.0 indicates the stock is in oversold territory, suggesting potential near-term recovery or pullback completion, though this may reflect profit-taking after significant price appreciation. The 50-day moving average of $1,179.91 sits above the current price of $1,145.83, while the 200-day moving average of $1,060.82 remains substantially lower, indicating an intermediate-term uptrend has begun to flatten or consolidate. This divergence between short-term and intermediate moving averages suggests weakening momentum, corroborated by the D-grade in momentum factors, signaling caution for continuation of the previous rally. Price stability near the 50-day MA may represent a consolidation zone before further directional movement.
Analyst & Insider Sentiment
The analyst consensus rating of "Buy" with an average price target of $1,055.92 provides marginal downside protection, suggesting consensus views expect minimal further appreciation from current levels. However, insider activity paints a mixed picture—recent transactions by executives Zakrowski, Hakim, and Seymour involve net selling of approximately 8,019 shares (despite one small buy of 1,506 shares by Seymour), which typically signals insiders believe valuations are extended. The timing of these insider sales in early August 2026, concurrent with an earnings beat, suggests confidence in fundamentals but caution about valuation sustainability. Such selling patterns are generally viewed as a cautionary signal, particularly when occurring at elevated price levels.
The most significant risk is valuation compression, with the 55.2% downside to fair value representing substantial potential drawdown if growth expectations moderate or market sentiment shifts. Pharmaceutical companies face inherent regulatory, clinical trial, and patent expiration risks that are not explicitly quantified in current metrics but warrant consideration for a company of LLY's pipeline-dependent profile. The D-grade momentum score combined with oversold RSI suggests technical fragility, indicating the stock may be vulnerable to profit-taking or market rotation out of expensive growth healthcare names. Additionally, the neutral news sentiment and lack of recent positive catalysts could weigh on near-term price action if earnings surprises cease or forward guidance disappoints.
Eli Lilly presents a classic "growth at an expensive price" scenario where strong operational execution and earnings beats have driven valuation multiples far ahead of intrinsic value estimates, creating asymmetric risk-reward unfavorable for new buyers at current levels. While the company's B-grade growth prospects and consistent earnings outperformance justify a premium valuation, the 49x P/E ratio leaves limited margin of safety and requires near-perfect execution to justify further appreciation. Conservative investors should consider waiting for either a 10-15% pullback to the $1,000-1,050 range, alignment with analyst consensus targets, or stronger fundamental catalysts before initiating positions. Current shareholders may consider partial profit-taking given insider selling patterns and technical weakness, while existing bulls should maintain positions only with conviction in exceptional long-term growth prospects that justify sustained premium valuations.
